Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
10/21/2020 10/22/2020 10/23/2020 10/26/2020 10/27/2020 Date
42.5(c) 42.33(c) 42.425(c) 42.555(c) 41.91 Last
5 096 131 4 219 432 3 210 078 3 902 961 3 777 683 Volume
-2.57% -0.40% +0.22% +0.31% -1.52% Change
More quotes
Financials
Sales 2020 42 947 M 50 817 M 50 817 M
Net income 2020 -4 852 M -5 741 M -5 741 M
Net Debt 2020 32 409 M 38 348 M 38 348 M
P/E ratio 2020 -7,02x
Yield 2020 5,68%
Sales 2021 43 350 M 51 293 M 51 293 M
Net income 2021 3 803 M 4 499 M 4 499 M
Net Debt 2021 31 257 M 36 984 M 36 984 M
P/E ratio 2021 11,7x
Yield 2021 5,70%
Capitalization 41 807 M 49 406 M 49 468 M
EV / Sales 2020 1,73x
EV / Sales 2021 1,69x
Nbr of Employees 101 168
Free-Float 100,0%
More Financials
Company
Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Sales are distributed by product family as follows: - agrochemicals (45.5%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (41.2%) : intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc. ; - OTC... 
Sector
Pharmaceuticals
Calendar
11/03 | 07:30amErgebnisveröffentlichung
More about the company
Notations Surperformance© of Bayer AG
Trading Rating : Investor Rating :
More Ratings
All news about BAYER AG
12:50pCovestro reports third-quarter profit beat on strong Asia, furniture units
RE
09:47aBAYER : Rivaroxaban application submitted to U.S. FDA for new indication in pati..
AQ
09:46aBAYER : acquires Asklepios BioPharmaceutical to broaden innovation base in cell ..
AQ
09:32aBAYER : Appoints New Head of R&D at Pharmaceuticals
DJ
09:10aBAYER : appoints Dr. Christian Rommel as new Head of Pharmaceuticals Research an..
PU
05:51aCapgemini shares advance on better-than-expected Q3 growth
RE
10/26Health Care Shares Decline as Covid-19 Continues to Dominate Headlines -- Hea..
DJ
10/26NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/26NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/26NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/26WALL STREET STOCK EXCHANGE : US companies under China sanctions, Many acquisitio..
10/26BAYER : Finerenone significantly reduced renal and cardiovascular outcomes in pa..
AQ
10/26NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/26BAYER : Rivaroxaban application submitted to U.S. FDA for new indication in pati..
PU
10/26Bayer to acquire Asklepios Bio in foray into gene therapy worth up to $4 bill..
RE
More news
News in other languages on BAYER AG
10:58aBAYER : un nouveau chef pour la recherche pharmaceutique
10/26Aktien Europa Schluss: Zweite Corona-Welle sorgt für Flucht aus Risiken
10/26FRANKFURT STOCK EXCHANGE : La Bourse de Francfort clôture en baisse de 3,71%, pl..
10/26Résumé des principales informations économiques du lundi 26 octobre 2020
10/26DPA-AFX-ÜBERBLICK : UNTERNEHMEN vom 26.10.2020 - 15.15 Uhr
More news
Analyst Recommendations on BAYER AG
More recommendations
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 67,53 €
Last Close Price 42,56 €
Spread / Highest target 116%
Spread / Average Target 58,7%
Spread / Lowest Target 8,10%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Norbert Winkeljohann Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG-41.55%49 406
JOHNSON & JOHNSON-1.30%379 007
ROCHE HOLDING AG-4.55%282 543
PFIZER INC.-3.22%210 717
MERCK & CO., INC.-13.32%199 405
NOVARTIS AG-16.94%185 381